News has that pharmaceutical giant Pfizer Global Supply will continue commercial and support operations at the Bristol, Tenn., facility despite the closure of its manufacturing and logistics operations.
With the acquisition of Bristol-based King Pharmaceuticals, Pfizer is attempting a merger of both the plants. As per a news release on Wednesday, Pfizer said that the production unit for thyroid therapy and pain medication would be relocated by 2014 from the underutilized facility to other site. The company is also said to combine Bristol’s logistics center with Pfizer’s existing distribution facility at Memphis.
Nearly 130 workers in manufacturing and 16 workers in logistics will be affected by the move. In an email, company representative Rick Chambers said that although the commercial and support operations at the Bristol facility employing nearly 166 staff has been scaled down lately, the unit will remain in Bristol.